文献速递儿童青少年精神精神分裂症与精神病性障碍心境障碍

丹麦iPSYCH2015队列:性染色体非整倍体与精神障碍风险的关联

Associations of psychiatric disorders with sex chromosome aneuploidies in the Danish iPSYCH2015 dataset: a case-cohort study.
PubMed 文献 · Lancet Psychiatry · 2023-01-01

临床检出率在45,X较高(93%),47,XXY(22%)、47,XXX(15%)、47,XYY(15%)较低。

要点

  • 性染色体非整倍体携带者精神障碍风险升高,以ADHD、ASD、精神分裂症谱系风险为主。
  • 47,XXY与重性抑郁风险升高相关,47,XXX与双相障碍风险升高相关。
  • 除45,X外,性染色体非整倍体临床检出率低,提示需加强临床基因检测。

核心结论

  • 性染色体非整倍体与多种索引精神障碍风险升高相关,而临床诊断率偏低,可能影响患者及家庭的医疗与咨询。

研究设计与样本

  • 丹麦iPSYCH2015病例-队列研究,源人群为1981年5月1日至2008年12月31日出生于丹麦的单胎个体。
  • 病例样本为截至2015年12月31日在丹麦精神科中央研究登记系统注册、诊断为任一索引精神障碍的全部个体;队列为源人群中随机选取的个体。
  • 对病例与队列样本的库血进行基因分型与质控过滤后,用微阵列数据检测性染色体非整倍体核型(45,X、47,XXX、47,XXY、47,XYY)。
  • 采用加权Cox比例风险模型估计各核型与各索引精神障碍风险的关联,并比较丹麦国家患者登记系统中的临床遗传诊断记录与研究检测核型以确定临床检出率。

关键数值与推荐

  • 临床检出率:45,X为93%,47,XXY为22%,47,XXX为15%,47,XYY为15%。

临床怎么用

  • 对精神障碍患者,尤其ADHD、孤独症谱系障碍、精神分裂症谱系障碍患者,可考虑性染色体非整倍体遗传检测以提高检出。
  • 性染色体非整倍体临床检出率低,提示需在临床环境中增加基因检测应用以改善医疗与咨询。

局限性

  • ethnicity信息不可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased prevalence of mental illness has been reported in clinical studies of sex chromosome aneuploidies, but accurate population-based estimates of the prevalence and clinical detection rate of sex chromosome aneuploidies and the associated risks of psychiatric disorders are needed. In this study, we provide such estimates, valid for children and young adults of the contemporary Danish population. METHODS: We used the iPSYCH2015 case-cohort dataset, which is based on a source population of single-born individuals born in Denmark between May 1, 1981, and Dec 31, 2008. The case sample comprises all individuals from the source population with a diagnosis of any index psychiatric disorder (schizophrenia spectrum disorder, bipolar disorder, major depressive disorder, autism spectrum disorder, or ADHD) by the end of follow-up (Dec 31, 2015), registered in the hospital-based Danish Psychiatric Central Research Register. The cohort consists of individuals randomly selected from the source population, and overlaps with the case sample. Biobanked blood samples for individuals in the case and cohort samples underwent genotyping and quality-control filtering, after which we analysed microarray data to detect sex chromosome aneuploidy karyotypes (45,X, 47,XXX, 47,XXY, and 47,XYY). We estimated the population-valid prevalence of these karyotypes from the cohort sample. Weighted Cox proportional hazards models were used to estimate the risks of each index psychiatric disorder associated with each sex chromosome aneuploidy karyotype, by use of date of first hospitalisation with the index disorder in the respective case group and the cohort as outcome. The clinical detection rate was determined by comparing records of clinical diagnoses of genetic conditions from the Danish National Patient Register with sex chromosome aneuploidy karyotype determined by our study. FINDINGS: The assessed sample comprised 119 481 individuals (78 726 in the case sample and 43 326 in the cohort) who had genotyped and quality-control-filtered blood samples, including 64 533 (54%) people of gonadal male sex and 54 948 (46%) of gonadal female sex. Age during follow-up ranged from 0 to 34·7 years (mean 10·9 years [SD 3·5 years]). Information on ethnicity was not available. We identified 387 (0·3%) individuals as carriers of sex chromosome aneuploidies. The overall prevalence of sex chromosome aneuploidies was 1·5 per 1000 individuals. Each sex chromosome aneuploidy karyotype was associated with an increased risk of at least one index psychiatric disorder, with hazard ratios (HRs) of 2·20 (95% CI 1·42-3·39) for 47,XXY; 2·73 (1·25-6·00) for 47,XXX; 3·56 (1·01-12·53) for 45,X; and 4·30 (2·48-7·55) for 47,XYY. All karyotypes were associated with an increased risk of ADHD (HRs ranging from 1·99 [1·24-3·19] to 6·15 [1·63-23·19]), autism spectrum disorder (2·72 [1·72-4·32] to 8·45 [2·49-28·61]), and schizophrenia spectrum disorder (1·80 [1·15-2·80] to 4·60 [1·57-13·51]). Increased risk of major depressive disorder was found for individuals with 47,XXY (1·88 [1·07-3·33]) and 47,XYY (2·65 [1·12-5·90]), and of bipolar disorder for those with 47,XXX (4·32 [1·12-16·62]). The proportion of sex chromosome aneuploidy carriers who had been clinically diagnosed was 93% for 45,X, but lower for 47,XXY (22%), 47,XXX (15%), and 47,XYY (15%). Among carriers, the risk of diagnosis of at least one index psychiatric disorder did not significantly differ between those who had and had not been clinically diagnosed with sex chromosome aneuploidies (p=0·65). INTERPRETATION: Increased risks of psychiatric disorders associated with sex chromosome aneuploidies, combined with low rates of clinical diagnosis of sex chromosome aneuploidies, compromise the adequate provision of necessary health care and counselling to affected individuals and their families, which might be helped by increased application of genetic testing in clinical settings. FUNDING: Lundbeck Foundation and National Institutes of Health.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sánchez XC, Montalbano S, Vaez M, et al. Associations of psychiatric disorders with sex chromosome aneuploidies in the Danish iPSYCH2015 dataset: a case-cohort study. Lancet Psychiatry. 2023. PMID: 36697121. doi:10.1016/S2215-0366(23)00004-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。